JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

RETRACTION: Development of the ARDS-Derived Gene Panel for Lung Adenocarcinoma Prognosis Stratification and Experiment Validation of CCL20 Expression

Environmental Toxicology +

|

November 25, 2024

|

November 25, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study on lung adenocarcinoma prognosis has been retracted due to a compromised peer review process. The development of an ARDS-derived gene panel for prognosis stratification is therefore invalidated.

Area Of Science

  • Environmental Toxicology
  • Oncology
  • Genetics

Background

  • Lung adenocarcinoma is a significant global health concern.
  • Accurate prognostic markers are crucial for effective patient management.
  • Acute Respiratory Distress Syndrome (ARDS) may offer insights into lung cancer progression.

Purpose Of The Study

  • To develop a gene panel derived from ARDS patients for stratifying lung adenocarcinoma prognosis.
  • To experimentally validate the expression of CCL20 in relation to lung adenocarcinoma.

Main Methods

  • Gene expression analysis in ARDS and lung adenocarcinoma cohorts.
  • Development of a predictive gene panel.
  • Experimental validation of CCL20 expression levels.

Main Results

  • A gene panel was developed for prognosis stratification.
  • CCL20 expression was investigated in the context of lung adenocarcinoma.
  • The article was retracted due to a compromised peer review process.

Conclusions

  • The findings presented in the original publication are invalidated due to the compromised peer review.
  • The integrity of the developed ARDS-derived gene panel and CCL20 validation is compromised.